Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand)

Researchers have developed a new approach to T cell therapy that is more effective in killing breast cancer cells. This new approach uses bispecific T cell engagers (BITEs) to redirect T cells to target and kill cancer cells. The researchers found that this approach was more effective than traditional T cell therapy and did not cause the same level of side effects. This is good news for patients with breast cancer, as it could lead to more effective and safer treatments.

เงินทุน

This work was supported by the National Research Council of Thailand (NRCT) (grant number N41A640177).

กระดาษต้นฉบับ

ชื่อบทความต้นฉบับ: Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L11
วารสาร: International Immunopharmacology
ดอย: https://doi.org/10.1016/j.intimp.2023.111012

จดหมายโต้ตอบ

Piriya Luangwattananun (email: [email protected]),
Pa-thai Yenchitsomanus (email: [email protected], [email protected])